The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer

The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer

Summary: Notwithstanding the positive clinical impact of endocrine therapies in estrogen receptor-alpha (ERα)-positive breast cancer, de novo and acquired resistance limits the therapeutic lifespan of existing drugs. Taking the position that resistance is nearly inevitable, we undertook a study to i...

Full description

Bibliographic Details
Main Authors: Kimberly J. Cocce, Jeff S. Jasper, Taylor K. Desautels, Logan Everett, Suzanne Wardell, Thomas Westerling, Robert Baldi, Tricia M. Wright, Kendall Tavares, Alex Yllanes, Yeeun Bae, Jeremy T. Blitzer, Craig Logsdon, Daniel P. Rakiec, David A. Ruddy, Tiancong Jiang, Gloria Broadwater, Terry Hyslop, Allison Hall, Muriel Laine, Linda Phung, Geoffrey L. Greene, Lesley-Ann Martin, Sunil Pancholi, Mitch Dowsett, Simone Detre, Jeffrey R. Marks, Gregory E. Crawford, Myles Brown, John D. Norris, Ching-yi Chang, Donald P. McDonnell
Format: Article
Language:English
Published: Elsevier 2019-10-01
Series:Cell Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124719312203

Internet

http://www.sciencedirect.com/science/article/pii/S2211124719312203

Similar Items